📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-11 15:39
666 analysed today
666
Today
133,555
All-time analysed
40,122
Positive
6,284
Negative
79,331
Neutral
7,750
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
₹300 Cr Capex: Bharat Parenterals Doubles Investment for Biologics & Oncology Facility
Bharat Parenterals' subsidiary, Varenyam Biolifesciences, has revised its Phase 1 capital expenditure for the Savli facility to ₹300 crore, doubling the previous estimate of ₹150 crore. The facility is being upgraded to include biologics and biosimilar CDMO capabilities alongside its existing oncology focus. This investment is highly material, representing approximately 87% of the company's TTM revenue and 93% of its net worth. The project targets high-regulated markets including the US and EU, with a targeted completion date of Q2 2028.
Confidence: HIGH
What changedThe company has doubled its investment and expanded the technical scope of its upcoming Savli facility to include high-value biologics CDMO services for regulated markets.
Why it mattersThis represents a major strategic pivot from a Rest-of-World focus to high-barrier, regulated markets (US/EU), which could significantly improve revenue quality and margins if successfully executed.
Revised Phase 1 Capex: ₹300 croreCapex vs TTM Revenue: ~87%Capex vs Net Worth: ~93%Previous Capex Plan: ₹150 croreTarget Completion: Q2 2028
📅 Short termThe announcement is likely to be viewed positively by the market as a major growth signal, though the long gestation period means no immediate impact on earnings.
📈 Long termIf the facility achieves USFDA/EU-GMP approval by 2028, it could structurally transform the company's P&L by entering the high-margin biologics CDMO space.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant execution risk
- Long gestation period (completion in 2028)
- High capital intensity relative to current net worth
- Regulatory approval risk (USFDA/EU-GMP)
Key Highlights
Revised Phase 1 capital expenditure of ₹300 crore, up from the previously planned ₹150 crore.
Facility upgrade to include biologics and biosimilar CDMO services for US, EU, and SRA markets.
Targeted completion date for the Savli manufacturing facility is Q2 2028.
Regulatory approvals to be pursued include USFDA, EU-GMP, and ANVISA.
Strategic shift to address the USD 24-27 billion global biologics CDMO market.
👀 What to Watch
Monitor the company's funding strategy for this ₹300 crore outlay given its current negative PAT and ROCE. Investors should track construction milestones and the eventual USFDA/EU-GMP inspection timeline toward 2028.
₹93.7 Cr Revenue: Bharat Parenterals Reports Q1 FY27 Loss Amid Subsidiary Scale-up
Bharat Parenterals reported a 19.2% YoY decline in consolidated revenue to ₹93.7 Cr for Q1 FY27, primarily due to a high base in the standalone business following the completion of a large ₹210 Cr institutional order. Despite the revenue drop, gross margins improved significantly by approximately 1,000 bps to 50.6% due to a better product mix. The company posted a consolidated net loss of ₹3.6 Cr, largely attributed to a ₹10.4 Cr loss at its Innoxel subsidiary, which is currently building capacity ahead of contracted revenue. Notably, subsidiaries Innoxel and Varenyam now contribute 46% of consolidated revenue, up from 21% a year ago.
Confidence: HIGH
What changedThe company is transitioning its revenue mix from standalone institutional tenders to subsidiary-led US/EU CDMO and domestic branded generics.
Why it mattersWhile the consolidated loss is a short-term headwind, the rapid growth of USFDA-compliant Innoxel and branded Varenyam suggests a structural shift toward higher-value pharmaceutical segments.
Consolidated Revenue (Q1): ₹93.7 CrRevenue vs TTM Revenue: 27.1%Gross Margin: 50.6%Innoxel Revenue Growth: 165% YoYConsolidated PAT: ₹(3.6) CrOwners Share of PAT: ₹1.0 Cr
📅 Short termThe stock may face pressure due to the consolidated net loss and the 19% YoY revenue decline, despite management's explanation of the high base effect.
📈 Long termThe long-term outlook depends on Innoxel's ability to leverage its USFDA EIR for high-margin US commercial supply and Varenyam's scaling in the domestic branded market.
⚠ Risk flags
- Continued losses at Innoxel subsidiary
- High operating expenses (41.5% of revenue)
- Execution risk in highly regulated US/EU markets
Key Highlights
Consolidated revenue declined 19.2% YoY to ₹93.7 Cr, representing ~27% of TTM revenue.
Gross margin expanded by 1,000 bps to 50.6%, keeping gross profit flat at ₹47.4 Cr despite lower volumes.
Innoxel subsidiary revenue surged 165% YoY to ₹21.4 Cr following USFDA EIR receipt.
Varenyam Healthcare reached a record revenue of ₹25.1 Cr with a 12.4% EBITDA margin.
Operating expenses rose 16.5% YoY to ₹38.9 Cr as the company builds ahead of forward revenue contracts.
👀 What to Watch
Monitor the EBITDA break-even timeline for the Innoxel subsidiary and the sustainability of the 50%+ gross margins as the business shifts from low-margin tenders to branded and CDMO sales.
Bharat Parenterals Q1 Results: Revenue Drops 19% YoY to ₹93.74 Cr, Returns to Profitability
Bharat Parenterals reported a consolidated revenue of ₹93.74 cr for Q1 FY27, marking a 19.2% decline from ₹116.00 cr in the same quarter last year. Despite the revenue drop, the company returned to a standalone net profit of ₹3.66 cr, a significant sequential improvement from the ₹8.16 cr loss in the preceding March quarter, though down 63.4% YoY. Consolidated EBITDA margins (excluding other income) contracted to 9.10% from 11.88% YoY. The board also approved the re-appointment of Mr. Hemang Shah as Executive Director for a five-year term.
Confidence: HIGH
What changedThe company has transitioned from a loss-making trend in the previous three quarters to a profitable Q1 FY27, although it faces significant YoY top-line and margin pressure.
Why it mattersFor a company with a high Price-to-Book ratio of 10.3 and a TTM loss of ₹27 cr, the sharp decline in revenue suggests growth challenges, even as cost controls helped achieve a quarterly profit.
Consolidated Revenue (Q1 FY27): ₹93.74 crYoY Revenue Growth: -19.2%Standalone Net Profit (Q1 FY27): ₹3.66 crConsolidated EBITDA Margin: 9.10%Q1 Revenue vs TTM Revenue: 27.1%
📅 Short termThe stock may face pressure due to the significant YoY decline in revenue and profit, despite the sequential turnaround from losses.
📈 Long termThe company needs to demonstrate consistent revenue growth and margin stabilization to justify its current valuation; the current contraction is a structural concern.
⚠ Risk flags
- Significant YoY revenue contraction
- Margin compression
- High valuation (P/B 10.3) relative to recent loss-making history
Key Highlights
Consolidated revenue from operations declined 19.2% YoY to ₹93.74 cr from ₹116.00 cr.
Standalone net profit stood at ₹3.66 cr, down 63.4% compared to ₹10.00 cr in Q1 FY26.
Consolidated EBITDA (excluding other income) fell to ₹8.53 cr from ₹13.78 cr in the year-ago period.
Consolidated EBITDA margin (excluding other income) compressed by 278 bps to 9.10%.
Re-appointment of Mr. Hemang Shah as Executive Director approved for a 5-year term starting August 2026.
👀 What to Watch
Investors should monitor if the company can sustain this return to profitability after a loss-making FY26, and watch for management commentary regarding the sharp 19% YoY revenue contraction.
Bharat Parenterals Q1 FY27: Standalone Net Profit at ₹3.66 Cr, Revenue Declines 19% YoY
Bharat Parenterals reported a consolidated revenue of ₹93.74 Cr for Q1 FY27, representing a 19.2% decline from ₹116.00 Cr in the same quarter last year. On a standalone basis, the company achieved a net profit of ₹3.66 Cr, a notable recovery from the ₹8.16 Cr loss reported in the preceding March 2026 quarter. Consolidated EBITDA margins (including other income) contracted to 10.29% from 12.79% YoY. The board also approved the re-appointment of Mr. Hemang Shah as Executive Director for a five-year term.
Confidence: HIGH
What changedThe company transitioned from a loss-making quarter in March 2026 to a profitable one in June 2026 on a standalone basis, despite a year-on-year revenue contraction.
Why it mattersAfter reporting a net loss of ₹27 Cr in FY26, returning to profitability is a critical step for the company to improve its negative ROCE (-2.0%) and justify its high P/B valuation of 10.3.
Consolidated Revenue (Q1 FY27): ₹93.74 CrStandalone Net Profit (Q1 FY27): ₹3.66 CrConsolidated EBITDA Margin: 10.29%Revenue vs TTM Revenue: ~27.2%Standalone Finance Costs: ₹0.69 Cr
📅 Short termThe return to standalone profitability may provide some support to the stock price, though the significant YoY revenue decline remains a concern.
📈 Long termThe company needs to demonstrate consistent revenue growth and margin expansion to recover from its recent annual losses and high debt-to-equity ratio of 0.45.
⚠ Risk flags
- Significant YoY revenue decline of 19.2%
- High P/B ratio of 10.3 relative to recent loss-making history
- Negative ROCE of -2.0%
Key Highlights
Consolidated Revenue from operations stood at ₹93.74 Cr, down from ₹116.00 Cr in Q1 FY26.
Standalone Net Profit reached ₹3.66 Cr, reversing a loss of ₹8.16 Cr in the previous quarter.
Consolidated EBITDA (including other income) was ₹9.65 Cr with a margin of 10.29%.
Standalone Finance Costs decreased to ₹0.69 Cr from ₹1.42 Cr in the year-ago period.
The 33rd Annual General Meeting is scheduled for September 19, 2026.
👀 What to Watch
Monitor the company's ability to sustain standalone profitability and reverse the YoY revenue decline in upcoming quarters. Watch for management commentary during the AGM on September 19 regarding the strategy to improve consolidated margins.
